Your price
RRP: £21.00
Save £0.71 (3%)
Dispatched within 4-6 working days.


How Excessive Government Regulation Stifles Pharmaceutical Innovation

By (author) Richard A. Epstein
Format: Paperback / softback
Publisher: Yale University Press, United States
Published: 2nd Jan 2009
Dimensions: w 156mm h 235mm d 18mm
Weight: 431g
ISBN-10: 0300143265
ISBN-13: 9780300143263
Barcode No: 9780300143263
This book is the first to offer a comprehensive examination of the pharmaceutical industry by following the tortuous course of a new drug as it progresses from early development to final delivery. Richard A. Epstein looks closely at the regulatory framework that surrounds all aspects of making pharmaceutical products today, and he assesses which current legal and regulatory practices make sense and which have gone awry. While critics of pharmaceutical companies call for ever more stringent controls on virtually every aspect of drug development and approval, Epstein cautions that the effect of such an approach will be to stifle pharmaceutical innovation and slow the delivery of beneficial treatments to the patients who need them. The author considers an array of challenges that confront the industry--conflicts of interest among government, academe, and the drug companies; intellectual property rights that govern patents; FDA regulation; pricing disputes; marketing practices; and liability issues, including those brought to light in the recent VIOXX case. Epstein argues that to ensure the continuing creativity, efficiency, and success of the pharmaceutical industry, the best system will feature strong property rights and clearly enforceable contracts, with minimal regulatory and judicial interference.

New & Used

Seller Information Condition Price

What Reviewers Are Saying

Be the first to review this item. Submit your review now